MedPath

Vifor Pharma, Inc.

🇺🇸United States
Ownership
Holding
Employees
-
Market Cap
-
Website

Clinical Trials

29

Active:23
Completed:1

Trial Phases

4 Phases

Phase 1:13
Phase 2:4
Phase 3:1
+1 more phases

Drug Approvals

1

FDA:1

Drug Approvals

VELTASSA

Approval Date
Nov 16, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials

Phase 1
13 (68.4%)
Phase 2
4 (21.1%)
Not Applicable
1 (5.3%)
Phase 3
1 (5.3%)

FDDA Utilization Study (FDDAU)

Not Applicable
Terminated
Conditions
Fatigue
First Posted Date
2023-05-17
Last Posted Date
2023-05-17
Lead Sponsor
Vifor Pharma, Inc.
Target Recruit Count
217
Registration Number
NCT05861492
Locations
🇨🇭

QualiPro Schweiz AG, Kriens, Luzern, Switzerland

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

Phase 2
Recruiting
Conditions
Hyperkalemia
Interventions
First Posted Date
2023-03-13
Last Posted Date
2025-06-27
Lead Sponsor
Vifor Pharma, Inc.
Target Recruit Count
36
Registration Number
NCT05766839
Locations
🇧🇪

Universitair Ziekenhuis Gent, Gent, Belgium

🇬🇷

Ippokratio Thessaloniki General Hospital, Thessaloníki, Thessaloniki, Greece

🇬🇷

Pan and Aglaia Kyriakou Children's Hospital, Athens, Greece

and more 9 locations

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Phase 3
Completed
Conditions
Hyperkalemia
Interventions
Drug: Placebos
First Posted Date
2019-03-25
Last Posted Date
2023-02-24
Lead Sponsor
Vifor Pharma, Inc.
Target Recruit Count
1195
Registration Number
NCT03888066
Locations
🇺🇸

Investigator Site 11-080, Alexander City, Alabama, United States

🇺🇸

Investigator Site 11-041, Huntsville, Alabama, United States

🇺🇸

Investigator Site 11-153, Phoenix, Arizona, United States

and more 412 locations

Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia

Phase 2
Terminated
Conditions
Hyperkalemia
Interventions
First Posted Date
2017-03-22
Last Posted Date
2022-10-19
Lead Sponsor
Vifor Pharma, Inc.
Target Recruit Count
23
Registration Number
NCT03087058
Locations
🇺🇸

Investigator Site 1107, Palo Alto, California, United States

🇺🇸

Investigator Site 1101, Kansas City, Kansas, United States

🇺🇸

Investigator Site 1103, Baltimore, Maryland, United States

and more 27 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.